Pipeline « « Sirona Biochem

By: Sirona Biochem  09-12-2011
Keywords: Preclinical Studies, Biological Ingredients, Pharmaceutical Partner,

Pipeline « « Sirona Biochem

Sirona Biochem specializes in the development of carbohydrate-based molecules. While carbohydrate-based molecules offer immense commercial potential, we are focused on advancing three programs – therapeutics, cosmetic agents and biological ingredients.

Our most advanced program, a sodium glucose co-transporter (SGLT) for diabetes, achieved positive preclinical results. In a comparative study, Sirona Biochem’s SGLT inhibitor performed better than the leading drug candidate, Dapagliflozin (Bristol Myers Squibb & AstraZeneca) in this drug class.

Further preclinical studies of Sirona Biochem’s SGLT inhibitor to test for safety and toxicology are underway.   It is our intention to complete IND(Investigational New Drug)-enabling studies, then seek a pharmaceutical partner to handle the downstream clinical and commercial needs of our program.

While Sirona Biochem’s cosmetic agents and biological ingredients do not require the same extensive clinical or preclinical testing as therapeutics, it is our plan to conduct several studies to demonstrate their effectiveness and safety before seeking cosmetic and laboratory partners for the commercial application of our products.

Keywords: Biological Ingredients, Pharmaceutical Partner, Preclinical Studies,

Other products and services from Sirona Biochem


Biological Ingredients « « Sirona Biochem

By developing these modified glycopeptides, we aim to preserve the integrity of organs for a longer period of time, leading to an expanded geographical reach for organ matching and transplantation. Our chemistry technology platform can be used for the development of enhanced inducers for recombinant protein production and adjuvants for the preservation of stem/islet cells.


Cosmeceuticals - Sirona Biochem | Skin lightener cosmetics ingredients

Sirona Biochem is currently developing molecules that we believe can maintain the viability of adult skin’s fibroblasts and protect skin from oxidative stress and UV radiation. We believe this will give us access to the best knowledge and information on cosmetic advances as well as help us understand market needs. Demand of skin lighteners has been mainly driven by a desire to reverse sun damage and for the appearance of younger looking skin.


Therapeutics « « Sirona Biochem

Sirona Biochem’s technology platform of enhancing carbohydrate-based molecules has potential for the development of several blockbuster therapeutics for the treatment of diabetes, obesity, cancer, cardiovascular disease, pain and inflammation.